Northland Securities analyst Carl Byrnes maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $60. The company’s shares opened today at $46.32.
Byrnes observed:
“We are highly confident that the NDA will be accepted by the FDA and FINTEPLA will be approved in the late-1H2020 timeframe.”
According to TipRanks.com, Byrnes ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.7% and a 25.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Aridis Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $56.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $62.75 and a one-year low of $33.43. Currently, Zogenix has an average volume of 742.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
